Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome (V-INCEPTION)
Phase 1B/2A, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 as an adjunct to best available therapy alone for the treatment of adults with bacteremia due to Staphylococcus aureus.
Phase 1B/2A, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 as an adjunct to best available therapy alone for the treatment of adults with bacteremia due to Staphylococcus aureus.
Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)
Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia (MARIPOSA)
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia (MARIPOSA)
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19
https://clinicaltrials.gov/ct2/show/NCT04292899?cond=remdesivir&draw=2&rank=5
RANDOMIZED, CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF INTRAVITREAL AFLIBERCEPT COMPARED TO LASER PHOTOCOAGULATION IN PATIENTS WITH RETINOPATHY OF PREMATURITY (BUTTERFLEYE)
RANDOMIZED, CONTROLLED, MULTI-CENTER STUDY TO ASSESS
THE EFFICACY, SAFETY, AND TOLERABILITY OF INTRAVITREAL
AFLIBERCEPT COMPARED TO LASER PHOTOCOAGULATION IN
PATIENTS WITH RETINOPATHY OF PREMATURITY
Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)
Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)
Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Primary Objective:
To investigate effects of SAR440340 (anti-interleukin-33 [IL?33] monoclonal antibody [mAb]) compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over up to 52 weeks of treatment.
